Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE)

CUSIP: 00439U104

Q4 2025 13F Holders as of 31 Dec 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
16,654,455
Total 13F shares
4,327,617
Share change
+620,790
Total reported value
$14,995,992
Price per share
$3.46
Number of holders
22
Value change
+$2,269,248
Number of buys
11
Number of sells
4

Quarterly Holders Quick Answers

What is CUSIP 00439U104?
CUSIP 00439U104 identifies GRCE - Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE) as of Q4 2025

As of 31 Dec 2025, Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE) was held by 22 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 4,327,617 shares. The largest 10 holders included Nantahala Capital Management, LLC, AIGH Capital Management LLC, ADAR1 Capital Management, LLC, BANK OF AMERICA CORP /DE/, VANGUARD GROUP INC, Cerity Partners LLC, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, XTX Topco Ltd, and MORGAN STANLEY. This page lists 22 institutional shareholders reporting positions in this security for the Q4 2025 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.